Geneva Partners LLC Sells 428 Shares of Eli Lilly and Company (NYSE:LLY)

Geneva Partners LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 4.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,656 shares of the company’s stock after selling 428 shares during the period. Eli Lilly and Company accounts for approximately 2.8% of Geneva Partners LLC’s portfolio, making the stock its 12th largest holding. Geneva Partners LLC’s holdings in Eli Lilly and Company were worth $5,046,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Onyx Bridge Wealth Group LLC raised its stake in Eli Lilly and Company by 14.1% in the 4th quarter. Onyx Bridge Wealth Group LLC now owns 616 shares of the company’s stock valued at $359,000 after acquiring an additional 76 shares during the period. Wetzel Investment Advisors Inc. purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $5,588,000. Greenleaf Trust grew its holdings in Eli Lilly and Company by 21.9% during the 4th quarter. Greenleaf Trust now owns 29,034 shares of the company’s stock valued at $16,924,000 after buying an additional 5,210 shares in the last quarter. Naples Money Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $257,000. Finally, Zhang Financial LLC grew its holdings in Eli Lilly and Company by 2.1% during the 4th quarter. Zhang Financial LLC now owns 1,672 shares of the company’s stock valued at $975,000 after buying an additional 34 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 2.6 %

LLY stock traded down $19.64 during midday trading on Friday, hitting $726.31. The company had a trading volume of 3,486,055 shares, compared to its average volume of 3,073,465. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $369.76 and a 52 week high of $800.78. The stock’s 50 day moving average price is $763.96 and its 200 day moving average price is $659.59. The stock has a market cap of $690.11 billion, a price-to-earnings ratio of 125.23, a PEG ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the company posted $2.09 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Bank of America boosted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.